Literature DB >> 35316356

Psoriasis and Cardiovascular Risk in Children: The Usefulness of Carotid Intima-Media Thickness.

Iria Neri1, Marcello Lanari2, Marianna Fabi2, Marco A Chessa1, Davide Panizza3, Ada Dormi4, Anna Gazzano2, Annalisa Patrizi1, Federico Bardazzi1, Alessandro Rocca2, Emanuele Filice2.   

Abstract

Psoriasis is a skin disorder which mostly affects adults, beginning in childhood in almost one-third of patients. In adults it is associated with increased risk for cardiovascular diseases (CVD), while this association is still debated at younger age. Our aim was to evaluate the association between psoriasis and metabolic markers and cardiovascular findings in this age group. Twenty consecutive patients previously diagnosed with psoriasis (group A) were enrolled and compared with healthy non- psoriatic age- and sex-matched subjects (group B). The severity of the disease, CV risk factors, including anthropometric data with adiposity and its distribution, blood pressure (BP), laboratory metabolic tests, echocardiography and vascular ultrasound (transcranial echo-Doppler and carotid artery echo-Doppler with carotid intima-media thickness, cIMT) were performed for each subject. Personal history for CV risk, BP, anthropometric data were similar between the two groups, while familiar history for psoriasis was more frequent in group A (p < 0.02). C-IMT was significantly higher in group A compared to B (right, p = 0.001; left, p = 0.002). In addition, c-IMT was positively correlated with disease duration, triglycerides and triglycerides/glucose. Cerebral flow velocities, cardiac measurements, systo-diastolic function, ventricle geometry and mass were normal and comparable between the two groups, and did not correlate with CV risk factors. In childhood psoriasis c-IMT could represent a marker of pre-clinical cardiovascular involvement and contribute to start a personalized management, while cardiac findings seem to be normal in the early stage of disease. Longitudinal studies can clarify the progression of CV involvement in paediatric-onset psoriasis.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiovascular risk; Children; Echocardiography; Metabolic syndrome; Psoriasis; Vascular ultrasound

Mesh:

Substances:

Year:  2022        PMID: 35316356     DOI: 10.1007/s00246-022-02869-1

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.838


  38 in total

1.  The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity.

Authors:  Wolf-Henning Boehncke; Sandra Boehncke; Anne-Marie Tobin; Brian Kirby
Journal:  Exp Dermatol       Date:  2011-04       Impact factor: 3.960

2.  Cardiovascular comorbidities in childhood psoriasis.

Authors:  Tiago Torres; Susana Machado; Denisa Mendonça; Manuela Selores
Journal:  Eur J Dermatol       Date:  2014 Mar-Apr       Impact factor: 3.328

3.  Pediatric Psoriasis Comorbidity Screening Guidelines.

Authors:  Emily Osier; Audrey S Wang; Megha M Tollefson; Kelly M Cordoro; Stephen R Daniels; Andrew Eichenfield; Joel M Gelfand; Alice B Gottlieb; Alexa B Kimball; Mark Lebwohl; Nehal N Mehta; Amy S Paller; Jeffrey B Schwimmer; Dennis M Styne; Abby S Van Voorhees; Wynnis L Tom; Lawrence F Eichenfield
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

Review 4.  The epidemiology of childhood psoriasis: a scoping review.

Authors:  E Burden-Teh; K S Thomas; S Ratib; D Grindlay; E Adaji; R Murphy
Journal:  Br J Dermatol       Date:  2016-05-22       Impact factor: 9.302

5.  Comprehensive lipid tetrad index, atherogenic index and lipid peroxidation: Surrogate markers for increased cardiovascular risk in psoriasis.

Authors:  S Sunitha; Medha Rajappa; Devinder Mohan Thappa; Laxmisha Chandrashekar; Malathi Munisamy; G Revathy; M Priyadarssini
Journal:  Indian J Dermatol Venereol Leprol       Date:  2015 Sep-Oct       Impact factor: 2.545

6.  Cardiovascular comorbidities of pediatric psoriasis among hospitalized children in the United States.

Authors:  Lauren Kwa; Michael C Kwa; Jonathan I Silverberg
Journal:  J Am Acad Dermatol       Date:  2017-09-28       Impact factor: 11.527

7.  Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis.

Authors:  Nehal N Mehta; Ron Li; Parasuram Krishnamoorthy; YiDing Yu; William Farver; Amrith Rodrigues; Anna Raper; Mackenzie Wilcox; Amanda Baer; Stephanie DerOhannesian; Megan Wolfe; Muredach P Reilly; Daniel J Rader; Abby VanVoorhees; Joel M Gelfand
Journal:  Atherosclerosis       Date:  2012-07-21       Impact factor: 5.162

Review 8.  Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis.

Authors:  Eleanor J Samarasekera; Julie M Neilson; Richard B Warren; Jill Parnham; Catherine H Smith
Journal:  J Invest Dermatol       Date:  2013-02-21       Impact factor: 8.551

9.  Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study.

Authors:  Wenqing Li; Jiali Han; Frank B Hu; Gary C Curhan; Abrar A Qureshi
Journal:  J Invest Dermatol       Date:  2011-10-13       Impact factor: 8.551

10.  Abnormal calcium cycling and cardiac arrhythmias associated with the human Ser96Ala genetic variant of histidine-rich calcium-binding protein.

Authors:  Vivek P Singh; Jack Rubinstein; Demetrios A Arvanitis; Xiaoping Ren; Xiaoqian Gao; Kobra Haghighi; Mark Gilbert; Venkat R Iyer; Do Han Kim; Chunghee Cho; Keith Jones; John N Lorenz; Clara F Armstrong; Hong-Sheng Wang; Sandor Gyorke; Evangelia G Kranias
Journal:  J Am Heart Assoc       Date:  2013-10-14       Impact factor: 5.501

View more
  1 in total

Review 1.  Oxidative Stress Induced by High Salt Diet-Possible Implications for Development and Clinical Manifestation of Cutaneous Inflammation and Endothelial Dysfunction in Psoriasis vulgaris.

Authors:  Ivana Krajina; Ana Stupin; Marija Šola; Martina Mihalj
Journal:  Antioxidants (Basel)       Date:  2022-06-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.